GlobeNewswire

Nexstim Receives Two New NBS System Orders in the United States

Share

Press release, Helsinki, 26 March 2020 at 9.30 am (EET)

Nexstim Receives Two New NBS System Orders in the United States

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has recently received two new NBS System orders from two large medical institutions in the United States.

Nexstim NBS System uses Company’s unique SmartFocus® TMS technology that enables accurate stimulation of the targeted area in patient’s brain. NBS System is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain. 

Nexstim NBS systems are used mainly for neurosurgical diagnostics: One of the most crucial pieces of information needed for neurosurgery is the tumour’s location in relation to the essential functions and their connections in the patient’s brain. SmartFocus® nTMS mapping with Nexstim’s NBS system can give this information regarding motor and speech areas — it can be invaluable when deciding the best treatment option.

Like Nexstim’s NBT® systems, NBS Systems are used worldwide also in conducting research concerning treatment and diagnostics of several different brain diseases and disorders.

Mikko Karvinen, CEO of Nexstim Plc commented: “We are happy to welcome these two medical institutions in the United States to our SmartFocus® user family where several renowned medical institutions around the world already use the NBS systems.TheNBS business remains a good and steady revenue source for Nexstim, also during these unfortunate times of COVID-19, as neurosurgical operations are still in place in many hospitals.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen1.6.2020 19:30:00 CESTPressemelding

Företagsmeddelande, insiderinformation, Helsingfors 1 juni 2020 kl. 20.30 (EEST) Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen FÅR EJ PUBLICERAS ELLER SPRIDAS DIREKT ELLER INDIREKT I FÖRENTA STATERNA, AUSTRALIEN, SYDAFRIKA, HONGKONG, JAPAN, KANADA, SINGAPORE ELLER NÅGON ANNAN STAT DÄR SPRIDNINGEN ELLER PUBLICERINGEN STRIDER MOT LAGEN. Teckningstiden för Nexstim Abp:s (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) företrädesemission om cirka 2,3 miljoner euro (”emissionen”) avslutades 25 maj 2020 i Sverige och 27 maj 2020 i Finland. Enligt det preliminära emissionsutfallet övertecknades emissionen och cirka 273 procent av de tilldelade aktierna tecknades. Av de tilldelade 376 719 780 nya aktierna (”emissionsaktierna”) tecknades 336 033 654 emissionsaktier (cirka 89,2 procent av emissionsaktierna) med företrädesrätt och 40 686 126 emissionsaktier (cirka 10,8 procent av emissionsaktierna) tilldelas i enlighet med emissionsvillkoren. Enligt det preliminära emissio

Nexstim Plc: Preliminary results of the successful rights issue1.6.2020 19:30:00 CESTPress release

Company announcement, inside information, Helsinki, 1 June 2020 at 8:30 pm (EEST) Nexstim Plc: Preliminary results of the successful rights issue NOT FOR PUBLICATION OR DISTRIBUTION, EITHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, SOUTH AFRICA, HONG KONG, JAPAN, CANADA OR SINGAPORE, OR IN ANY OTHER COUNTRY WHERE PUBLICATION OR DISTRIBUTION WOULD BE AGAINST THE LAW. The subscription period of Nexstim Plc’s (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “the Company”) rights issue of approximately EUR 2.3 million (“the Share Issue”) ended on 25 May 2020 in Sweden and on 27 May 2020 in Finland. The preliminary results indicate that the Share Issue was oversubscribed and a total of 273% shares were subscribed for of the shares offered. Of the 376,719,780 new shares offered in the Share Issue (“the Offer Shares”), 336,033,654 Offer Shares (approximately 89,2% of the Offer Shares) were subscribed using subscription rights which means that 40,686,126 Offer Shares (approximately 10.8% of

Kinnevik: Valberedning inför årsstämman 20211.6.2020 17:00:00 CESTPressemelding

I enlighet med beslutet vid årsstämman 2020 i Kinnevik AB (publ) (”Kinnevik”) har en valberedning sammankallats, bestående av ledamöter utsedda av Kinneviks röstmässigt största aktieägare. Valberedningen består av Cristina Stenbeck utsedd av Verdere S.à r.l. och CMS Sapere Aude Trust, Hugo Stenbeck utsedd av Alces Maximus LLC, James Anderson utsedd av Baillie Gifford, Anders Oscarsson utsedd av AMF Försäkring & Fonder, Marie Klingspor och Ramsay Brufer utsedd av Alecta. Anders Oscarsson har utsetts till ordförande i valberedningen. Information om valberedningens arbete finns på Kinneviks hemsida, www.kinnevik.com. Aktieägare som önskar lämna förslag till valberedningen kan göra det i skrift till agm@kinnevik.com eller till Valberedningen, Kinnevik AB, Box 2094, 103 13 Stockholm. För ytterligare information, besök www.kinnevik.com eller kontakta: Torun Litzén, Informations- och IR-chef Telefon +46 (0)70 762 00 50 Email press@kinnevik.com Kinnevik är ett sektorfokuserat investmentbolag s

Kinnevik: Nomination committee ahead of the 2021 Annual General Meeting1.6.2020 17:00:00 CESTPress release

In accordance with the resolution of the 2020 Annual General Meeting in Kinnevik AB (publ) (“Kinnevik”), a Nomination Committee has been convened comprising members appointed by Kinnevik’s largest shareholders in terms of voting interest. The Nomination Committee comprises Cristina Stenbeck appointed by Verdere S.à r.l. and CMS Sapere Aude Trust, Hugo Stenbeck appointed by Alces Maximus LLC, James Anderson appointed by Baillie Gifford, Anders Oscarsson appointed by AMF Insurance & Funds, Marie Klingspor and Ramsay Brufer appointed by Alecta. Anders Oscarsson has been appointed Committee Chairman. Information about the work of the Nomination Committee can be found on Kinnevik’s website at www.kinnevik.com. Shareholders wishing to submit proposals to the Nomination Committee can do so in writing to agm@kinnevik.com or to the Nomination Committee, Kinnevik AB, P.O. Box 2094, SE-103 13 Stockholm Sweden. For further information, visit www.kinnevik.com or contact: Torun Litzén, Director Inve

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER1.6.2020 16:20:00 CESTPress release

Bid procedure on 3 June 2020 Certificate:Commercial paper issued in SEK by non-financial companies with a registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 3 December 2020 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 25 May 2020.Bids:Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date:Wednesday 3 June 2020Bid time:0900-0930 hours (CEST) on the Bid dateRequested volume: (corresponding nominal amount)SEK 4 billion Highest permitted bid volume: (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SE

Real People Investment Holdings Limited – Appointment of Director1.6.2020 15:00:00 CESTPress release

The board of Real People Investment Holdings Limited has elected to appoint Mr Ralph Buddle as a non-executive director of the company, with effect from 1 June 2020. Mr Buddle is an experienced senior executive and chartered accountant with 35 years’ experience in retail and FMCG. With a background in corporate finance, M&A and strategy, he also has significant investor relations and corporate governance experience within the JSE Top-40 listed environment. * * * * * * * For further information, please contact: Neil Grobbelaar, Group Chief Executive Officer Email: ctaylor@realpeople.co.za Phone number: +27 82 772 5481 The information was submitted for publication, through the agency of the contact person set out above, on June 1st, 2020 at 15:00 CET Attachment RPIH Press Release - Appointment of director 20200528